OCS-01

Phase 2Small molecule

QQuan Dong Nguyen

OCS-01 is one of 8 small molecule programs targeting Cystoid Macular Edema. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cystoid Macular EdemaActive, not recruiting

Cystoid Macular EdemaPhase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Cystoid Macular Edema

#DrugCompanyPhaseTrials

Voltaren

Novartis

Approved

1 2

Decadron

AAspen Global Incorporated

Approved

2 3

Kenalog

BBausch Health Americas, Inc.

Approved

2 4

Ilevro

HHarrow Inc

Approved

2 5

Toradol

Vabysmo

OCS-01

1 8

Macugen

BBausch Health Americas, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cataract1 trial

A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Completed·OOculis·Phase 3·NCT05147233·241 enrolled

Cystoid Macular Edema1 trial

Efficacy and Safety of Dexamethasone ophthaLmic Suspension Eye drOps in Uveitic and Post Surgical mAculaR eDema (The LEOPARD Study)

Active, not recruiting·QQuan Dong Nguyen·Phase 2·NCT05608837·28 enrolled

Eye Pain1 trial

A Randomized, Double-masked, Vehicle-controlled Study Evaluating the Efficacy and Safety of OCS-01 Ophthalmic Suspension in the Treatment of Inflammation and Pain Following Cataract Surgery

Terminated·OOculis·Phase 3·NCT06128369·117 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for OCS-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OCS-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OCS-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Quan Dong Nguyen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: QQuan Dong Nguyen

OCS-01

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cataract1 trial

Cystoid Macular Edema1 trial

Eye Pain1 trial

References

Drug Info

Quick Facts

Related News